These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 21723218)

  • 21. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
    Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
    Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.
    Overholt BF; Wang KK; Burdick JS; Lightdale CJ; Kimmey M; Nava HR; Sivak MV; Nishioka N; Barr H; Marcon N; Pedrosa M; Bronner MP; Grace M; Depot M;
    Gastrointest Endosc; 2007 Sep; 66(3):460-8. PubMed ID: 17643436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
    Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
    Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
    Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
    Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of Barrett's high-grade dysplasia.
    Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
    Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
    Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
    Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.
    Khoshiwal AM; Frei NF; Pouw RE; ; Smolko C; Arora M; Siegel JJ; Duits LC; Critchley-Thorne RJ; Bergman JJGHM
    Gastroenterology; 2023 Nov; 165(5):1168-1179.e6. PubMed ID: 37657759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
    Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
    Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
    Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent disease following endoscopic ablation of Barrett's high-grade dysplasia with spray cryotherapy.
    Halsey KD; Chang JW; Waldt A; Greenwald BD
    Endoscopy; 2011 Oct; 43(10):844-8. PubMed ID: 21826629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus.
    Coco DP; Goldblum JR; Hornick JL; Lauwers GY; Montgomery E; Srivastava A; Wang H; Odze RD
    Am J Surg Pathol; 2011 Jan; 35(1):45-54. PubMed ID: 21164286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.
    Vennalaganti P; Kanakadandi V; Goldblum JR; Mathur SC; Patil DT; Offerhaus GJ; Meijer SL; Vieth M; Odze RD; Shreyas S; Parasa S; Gupta N; Repici A; Bansal A; Mohammad T; Sharma P
    Gastroenterology; 2017 Feb; 152(3):564-570.e4. PubMed ID: 27818167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.